Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Functional Information in Coronary Artery Disease: The Case of Computed Tomography Myocardial Perfusion

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Off-pump versus on-pump coronary artery bypass grafting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Pharmacogenomics and cardiovascular disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Shared heritability and functional enrichment across six solid cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

PURPOSE OF REVIEW: To summarize and discuss the clinical use of lipid and apolipoprotein tests in the settings of diagnosis and therapeutic follow-up of hyperlipidemia.

RECENT FINDINGS: The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently produced recommendations on the measurement of atherogenic lipoproteins, taking into account the strengths and weaknesses of analytical and clinical performances of the tests. Total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and calculated non-HDL cholesterol (= LDL + remnant cholesterol) constitute the primary lipid panel for hyperlipidemia diagnosis and cardiovascular risk estimation. LDL cholesterol is the primary target of lipid-lowering therapies. Non-HDL cholesterol or apolipoprotein B should be used as secondary therapeutic target in patients with mild-to-moderate hypertriglyceridemia, 2-10 mmol/l (175-880 mg/dl). Lipoprotein (a) is included in LDL cholesterol and should be measured at least once in all patients at cardiovascular risk, including to explain poor response to statin treatment.

OriginalsprogEngelsk
TidsskriftCurrent Cardiology Reports
Vol/bind20
Udgave nummer10
Sider (fra-til)88
ISSN1534-3170
DOI
StatusUdgivet - 17 aug. 2018

ID: 56621711